Key Takeaways
- Cellectis will announce its Q1 2026 financial results on May 11, 2026, after US market close.
- The press release will be available in the Investors section of Cellectis’ website.
- No conference call will be held; investor inquiries can be directed via email.
Company Overview
Cellectis, a clinical-stage biotechnology company, is recognized for its innovative gene-editing platform aimed at developing life-saving cell and gene therapies. Specializing in oncology, Cellectis employs an allogeneic approach for CAR T immunotherapies, focusing on creating off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment. This unique methodology places Cellectis among a select group of companies that manage the entire cell and gene therapy value chain, thanks to their in-house manufacturing capabilities.
Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC. The company is listed both on the Nasdaq Global Market under ticker CLLS and on Euronext Growth under ticker ALCLS.
On May 11, 2026, Cellectis plans to report its financial results for the first quarter of 2026, specifically ending March 31, 2026. This announcement will be accessible in the Investors section of their website. Unlike previous announcements, Cellectis will not host a conference call to discuss the financial results. Stakeholders and investors with questions can reach out to their investor relations team via email.
For more information regarding Cellectis and their initiatives in gene therapy, visit their official website or connect with them on social media platforms.
The content above is a summary. For more details, see the source article.